Faslodex (fulvestrant), a new drug for metastatic breast cancer
June 2002
You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.
It's for postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.
In these women, Faslodex delays tumor progression at least as well as the aromatase inhibitor Arimidex (anastrozole).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote